In a filing, NewAmsterdam Pharma Company NV revealed its 10% Owner ForGrowth NAP B.V. unloaded Company’s shares for reported $0.83 million on Nov 18 ’24. In the deal valued at $25.08 per share,33,273 shares were sold. As a result of this transaction, ForGrowth NAP B.V. now holds 11,778,760 shares worth roughly $245.47 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, ForGrowth NAP B.V. sold 8,530 shares, generating $213,436 in total proceeds. Upon selling the shares at $25.02, the 10% Owner now owns 11,812,033 shares.
Before that, ForGrowth NAP B.V. sold 9,832 shares. NewAmsterdam Pharma Company NV shares valued at $245,856 were divested by the 10% Owner at a price of $25.01 per share. As a result of the transaction, ForGrowth NAP B.V. now holds 11,820,563 shares, worth roughly $246.34 million.
TD Cowen initiated its NewAmsterdam Pharma Company NV [NAMS] rating to a Buy in a research note published recently. A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in mid March with a ‘”a Sector outperform”‘ rating. Guggenheim began covering NAMS with “Buy” recommendation on January 18, 2024. Piper Sandler started covering the stock on January 16, 2024. It rated NAMS as “an Overweight”.
Price Performance Review of NAMS
On Tuesday, NewAmsterdam Pharma Company NV [NASDAQ:NAMS] saw its stock fall -1.00% to $20.84. Over the last five days, the stock has lost -11.99%. NewAmsterdam Pharma Company NV shares have risen nearly 86.57% since the year began. Nevertheless, the stocks have risen 111.36% over the past one year. While a 52-week high of $26.35 was reached on 01/25/24, a 52-week low of $8.90 was recorded on 01/02/24. SMA at 50 days reached $19.28, while 200 days put it at $19.49.
Levels Of Support And Resistance For NAMS Stock
The 24-hour chart illustrates a support level at 19.91, which if violated will result in even more drops to 18.99. On the upside, there is a resistance level at 21.63. A further resistance level may holdings at 22.43. The Relative Strength Index (RSI) on the 14-day chart is 48.75, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.24, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 78.18%. Stochastics %K at 29.35% indicates the stock is a holding.
How much short interest is there in NewAmsterdam Pharma Company NV?
A steep rise in short interest was recorded in NewAmsterdam Pharma Company NV stocks on 2024-11-15, growing by 0.46 million shares to a total of 1.01 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-15 was 0.55 million shares. There was a rise of 45.57%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 30, 2023 when RBC Capital Mkts began covering the stock and recommended ‘”an Outperform”‘ rating along with a $25 price target.
